Start › Ostra białaczka szpikowa › Pensylwania › Philadelphia
Badania kliniczne dla Ostra białaczka szpikowa w mieście Philadelphia, PA
34 badań dla Ostra białaczka szpikowa szuka uczestników w ośrodkach w mieście Philadelphia i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
RekrutacjaFaza 2
- Thomas Jefferson University Hospital, Philadelphia
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekrutacjaFaza 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
RekrutacjaFaza 1
- Children's Hospital of Philadelphia, Philadelphia
Assessment of Geriatric Evaluations Impact on New AML Guidance
RekrutacjaBadanie obserwacyjne
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · 22 mi dalej
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekrutacjaBadanie obserwacyjne
- Children's Hospital of Philadelphia, Philadelphia
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RekrutacjaFaza 3
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekrutacjaFaza 2
- Thomas Jefferson University Hospital, Philadelphia
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekrutacjaFaza 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekrutacjaFaza 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekrutacjaFaza 3
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25 mi dalej
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RekrutacjaFaza 1/2
- University of Pennsylvania, Philadelphia
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
RekrutacjaFaza 1
- UPENN Perelman Center for Advanced Medicine, Philadelphia
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
RekrutacjaFaza 3
- Children's Hospital of Philadelphia, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25 mi dalej
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekrutacjaFaza 1/2
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · 25 mi dalej
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RekrutacjaFaza 3
- Children's Hospital of Philadelphia, Philadelphia
- Nemours Alfred I. Dupont Hospital for Children, Wilmington · 25 mi dalej
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekrutacjaFaza 3
- University of Pennsylvania, Philadelphia
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
RekrutacjaFaza 2/3
- University of Pennsylvania, Philadelphia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
RekrutacjaFaza 1
- Children's Hospital of Philadelphia, Philadelphia
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
RekrutacjaFaza 2
- Penn Medicine Abramson Cancer Center, Philadelphia
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
RekrutacjaFaza 1
- University of Pennsylvania, Philadelphia
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Rekrutacja
- Children's Hospital of Philadelphia, Philadelphia
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
RekrutacjaFaza 1
- Children's Hospital of Philadelphia, Philadelphia
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekrutacjaBadanie obserwacyjne
- Children's Hospital of Philadelphia, Philadelphia
- Nemours - Alfred I. duPont Hospital for Children, Brandywine · 21 mi dalej
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RekrutacjaFaza 1/2
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
RekrutacjaFaza 1
- University of Pennsylvania, Philadelphia
Massage Impact on Sleep in Pediatric Oncology
Rekrutacja
- Children's Hospital of Philadelphia, Philadelphia
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekrutacjaFaza 1/2
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Phase IB/II of CPX-351 for Relapse Prevention in AML
RekrutacjaFaza 1/2
- University of Pennsylvania, Philadelphia
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
RekrutacjaFaza 1
- Thomas Jefferson University Hospital, Philadelphia
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekrutacjaFaza 1
- Hospital of the University of Pennsylvania, Philadelphia
Tazemetostat and Palbociclib With CPX-351for R/R AML
RekrutacjaFaza 1
- Thomas Jefferson University Hospital, Philadelphia
Home Blood Transfusions
Rekrutacja
- Thomas Jefferson University Hospital, Philadelphia
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
RekrutacjaZapraszamy zdrowych ochotników
- University of Pennsylvania, Philadelphia
Badania dla Ostra białaczka szpikowa w innych miastach
- Houston, TX85 badań
- New York City, NY51 badań
- Boston, MA44 badań
- Seattle, WA41 badań
- Baldwin Park, CA40 badań
- Columbus, OH35 badań
- Durham, NC33 badań
- Atlanta, GA31 badań
- Tampa, FL29 badań
- Chicago, IL26 badań
- Portland, OR25 badań
- Washington, DC24 badań
Inne badania w mieście Philadelphia
- Nowotwory (wszystkie typy)59 badań
- Rak piersi56 badań
- Niedrobnokomórkowy rak płuca51 badań
- Nowotwór przerzutowy46 badań
- Rak prostaty44 badań
- Rak jelita grubego i odbytnicy44 badań
- Rak jajnika44 badań
- Rak płuc36 badań
- Niewydolność serca31 badań
- Rak endometrium28 badań
- Depresja26 badań
- Rak trzustki26 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.